Minneapolis Personal Injury Lawyer - Medication Safety Alerts

Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose

UPDATED 05/14/2012. New recommendations for monitoring patients, and new contraindications, and dosing & administration information for use in certain patients.

05/14/12 12:30 pm

Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject: Recall - May Contain More Than the Intended Fill Volume

An overdose of Hydromorphone may result in life-threatening consequences, including respiratory depression (slowed breathing or suspension of breathing), low blood pressure, and reduced heart rate including circulatory collapse.

05/14/12 12:05 pm

Revlimid (lenalidomide): Ongoing Safety Review - Increased Risk of Developing New Malignancies

UPDATED 05/07/2012. Increased risk of developing acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma in patients being treated with Revlimid.

05/07/12 12:20 pm

Certain Compounded Drugs from Franck's: FDA Issues Second Warning to Physicians

[UPDATED 05/04/2012] The Centers for Disease Control and Prevention (CDC) has advised healthcare personnel to avoid use of compounded products labeled as sterile from Franck’s during the ongoing investigation.

05/04/12 10:00 am

Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug Interactions

UPDATED 04/26/2012. Label revised to state that co-administration of Victrelis with certain ritonavir-boosted human immunodeficiency virus protease inhibitors is not recommended. Originally posted 02/09/2012

04/26/12 1:45 pm

X-Rock: Recall - Undeclared Drug Ingredient

Undeclared active ingredients may interact with nitrates found in some prescription drugs (such as nitroglycerin) and lower blood pressure to dangerous levels.

04/25/12 7:50 am

Roche Diagnostics Operations Elecsys Troponin I and Elecsys Troponin I STAT Immunoassays: Recall – Doctors may receive a falsely low result

Customers should immediately discontinue use of any affected product.

04/24/12 11:15 am

Brilliant Blue G Compounded by Franck's: Recall of Unapproved Drug - Ongoing Investigation of Fungal Endophthalmitis Cases

[UPDATED 05/04/2012] The Centers for Disease Control and Prevention (CDC) has advised healthcare personnel to avoid use of compounded products labeled as sterile from Franck’s during the ongoing investigation.

04/20/12 12:00 pm

Aliskiren-containing Medications: Drug Safety Comunication - New Warning and Contraindication

Risk of renal impairment, hypotension, and hyperkalemia with concomitant use of aliskiren with angiotensin receptor blockers (ARBs) or angiotensin converting enzyme inhibitors (ACEIs) in patients with diabetes.

04/20/12 10:38 am

Other‐Sonic Generic Ultrasound Transmission Gel: Safety Communication - Risk of Bacterial Contamination

Exposure to contaminated product may lead to serious infections.

04/18/12 12:30 pm

Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume

Consequences of opioid pain medication overdose can be life-threatening, including respiratory depression (slowed breathing or suspension of breathing), and low blood pressure.

04/18/12 8:00 am

Birth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots

Women should talk to their healthcare professional about their risk for blood clots before deciding which birth control method to use.

04/10/12 11:00 am